A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Jun 2017 Planned End Date changed from 19 May 2022 to 30 Apr 2022.
- 12 Jun 2017 Planned primary completion date changed from 9 May 2019 to 20 Apr 2019.
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.